ILSI-Biomed Israel

Avraham Pharmaceuticals: $9 M Funding for a Multy-functional Alzheimer drug

Avraham Pharmaceuticals Ltd. has raised $9 million from Yissum Research Development Company (the technology transfer arm of the Hebrew University of Jerusalem), Pontifax, Clal Biotechnology Industries (CBI), Professor Marta Weinstock-Rosin and others.   Yissum has announced that, together with the Technion Research and Development Foundation (TRDF), the technology transfer arm of the Technion Israel Institute of Technology, it will exclusively license to Avraham the commercial rights of La...

OrSense Receives FDA Approval for Non-Invasive Oximetry Monitoring System

OrSense Ltd., developer of monitors for non-invasive measurements of various blood parameters, announced it has received U.S. Food and Drug Administration (FDA) approval for NBM-200MP, a non-invasive oximetry and low signal oximetry sensor.   Non-invasive pulse oximetry has become a standard of care in the operating and recovery rooms, intensive care units and emergency services, yet it has been known to provide erroneous oxygen saturation readings in situations of low perfusion, low...

Israeli Argo Receives Public Attention

Israeli Argo Gets Its 15 Minutes of Fame on "Good Morning America" "Healing the paralyzed man" is a well developed concept in Christian USA, as since Jesus was told to do it once, many have tried to repeat the miracle and failed. But Argo Medical Technologies from Haifa, Israel, has done just that with no Demons cast out ceremony. Argo's device, ReWalk, is an upper body harness with full legs support that motorizes the hips and knees. The device's sensors supervise the motion, as the crut...

Valtech Cardio Raises $17.8 Million

Valtech Cardio Ltd. announced today that new and existing investors (OXO Capital Valve Ventures LLC, NGN Biomed Opportunity II, L.P., and Peregrine VC Investments II, L.P.) recently completed a Series B financing of $17.8 million. PRNewswire, OR YEHUDA, Israel. February 2, 2010 Valtech Cardio Ltd. announced today that new and existing investors (OXO Capital Valve Ventures LLC, NGN Biomed Opportunity II, L.P., and Peregrine VC Investments II, L.P.) recently completed a Series B financin...